8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy

Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy

Hematopoietic Stem Cell Transplantation (HSCT) and adoptive cellular therapies represent curative or life-prolonging modalities for hematologic malignancies and select non-malignant disorders. As the clinical indications expand and novel cellular products enter clinical practice, Oncology Nurse Practitioners (APRNs) play a pivotal role in pre-transplant evaluation, conditioning toxicity management, acute and chronic Graft-versus-Host Disease (GVHD) diagnosis, and cellular therapy toxicity mitigation.

---

1. Classifications, Donor Sources & Mobilization

Classifications of HSCT

• Autologous HSCT: Stem cells are collected from the patient, cryopreserved, and reinfused following high-dose myeloablative chemotherapy. Operates solely on the principle of high-dose chemo intensity; stem cells act as a hematopoietic rescue. Main indications: Multiple Myeloma, relapsed Hodgkin and non-Hodgkin Lymphoma.
• Allogeneic HSCT: Stem cells are harvested from a healthy donor (human leukocyte antigen [HLA]-matched sibling, matched unrelated donor [MUD], haploidentical family member, or umbilical cord blood). Operates on both chemotherapy conditioning and the immunological Graft-versus-Leukemia (GVL) effect, where donor immune cells eradicate residual recipient tumor cells. Main indications: Acute Leukemias (AML, ALL), Myelodysplastic Syndromes (MDS), Severe Aplastic Anemia.
• Syngeneic HSCT: Stem cells harvested from an identical twin (no GVHD, but no GVL effect).

Stem Cell Sources & Mobilization Protocols

1. Peripheral Blood Stem Cells (PBSC): Most common source ($>90%$). Mobilized from bone marrow into peripheral blood using daily G-CSF (filgrastim 10 mcg/kg/day) $\pm$ plerixafor (a CXCR4 chemokine receptor antagonist that releases stem cells bound to marrow stroma). Harvested via leukapheresis. Minimum target yield: $\ge 2.0 imes 10^6 ext{ CD34}^+ ext{ cells/kg}$.
2. Bone Marrow (BM): Harvested via multiple iliac crest aspirations under general anesthesia. Associated with lower risk of chronic GVHD compared to PBSC.
3. Umbilical Cord Blood: Rich in primitive stem cells; requires less stringent HLA matching, but associated with delayed engraftment.

---

2. Conditioning Regimens & Early Post-Transplant Complications

Conditioning Intensity

• Myeloablative Conditioning (MAC): High doses of chemotherapy $\pm$ Total Body Irradiation (TBI) (e.g., Busulfan/Cyclophosphamide, TBI/Etoposide) designed to completely eradicate host marrow and provide maximal immunosuppression. Causes irreversible marrow aplasia without stem cell rescue.
• Reduced-Intensity Conditioning (RIC) / Non-Myeloablative (NMA): Uses lower chemotherapy doses to suppress host immunity sufficiently to permit donor stem cell engraftment, relying primarily on GVL for disease control. Preferred in older or comorbid patients.

Early Complications (Days 0 to +30)

---

3. Acute vs. Chronic Graft-versus-Host Disease (GVHD)

GVHD occurs when immunocompetent donor T lymphocytes recognize recipient histocompatibility antigens as foreign, initiating an immunological attack against host tissues.

Donor T-Cell Activation (Allogeneic Graft)
  │
  ├── Onset < 100 Days: Acute GVHD (Inflammatory T-cell storm)
  │     ├── Target 1: Skin (Maculopapular rash -> Erythroderma)
  │     ├── Target 2: GI Tract (Watery green diarrhea > 500-1500 mL/day)
  │     └── Target 3: Liver (Cholestatic jaundice, elevated bilirubin)
  │
  └── Onset > 100 Days: Chronic GVHD (Fibrotic / Autoimmune-like)
        ├── Target 1: Skin (Scleroderma, lichen planus-like changes)
        ├── Target 2: Eyes / Mouth (Sicca syndrome, severe dry mouth/eyes)
        └── Target 3: Lungs (Bronchiolitis Obliterans Syndrome [BOS])

Acute GVHD (aGVHD)

• Timeline: Typically presents within 100 days post-transplant (peak onset days +20 to +50).
• Organ Manifestations & Staging:
  • Skin: Maculopapular rash starting on palms, soles, head, and neck. Stage 1 ($<25% ext{ BSA}$) to Stage 4 (generalized erythroderma with bullae and desquamation).
  • Gastrointestinal: Secretory, voluminous green watery diarrhea ($>500 ext{ mL/day}$ to $>1,500 ext{ mL/day}$), severe abdominal cramping, ileus, hematochezia.
  • Liver: Cholestatic jaundice with conjugated hyperbilirubinemia and elevated alkaline phosphatase.
• First-Line Treatment: High-dose systemic corticosteroids: Methylprednisolone 2 mg/kg/day IV (divided BID). Continue until response, then slow taper.
• Steroid-Refractory aGVHD: Defined as progression after 3 days or lack of response after 7 days of steroids. First-line FDA-approved second-line agent: Ruxolitinib (selective JAK1/JAK2 inhibitor, 10 mg PO BID).

Chronic GVHD (cGVHD)

• Timeline: Manifests $>100$ days post-transplant (or classic overlap features).
• Clinical Features: Resembles autoimmune connective tissue diseases. Sclerodermatous skin thickening, poikiloderma, severe dry eyes/mouth (sicca syndrome), oral lichen planus, esophageal web strictures, vaginal stenosis, and Bronchiolitis Obliterans Syndrome (BOS) (progressive obstructive airway disease with dry cough and dyspnea).
• Management: Systemic corticosteroids $\pm$ FDA-approved agents: Ruxolitinib, Belumosudil (ROCK2 inhibitor), or Ibrutinib (BTK inhibitor).

---

4. CAR T-Cell & Adoptive Cellular Therapies

Chimeric Antigen Receptor (CAR) T-cell therapy involves harvesting autologous T cells, genetically engineering them via viral vectors to express a synthetic receptor targeting tumor antigens (e.g., anti-CD19 in DLBCL/ALL; anti-BCMA in Multiple Myeloma), expanding them ex vivo, and reinfusing them following lymphodepleting chemotherapy (fludarabine/cyclophosphamide).

Major Toxicities & APRN Management

1. Cytokine Release Syndrome (CRS):
   • Pathophysiology: Massive immune activation releasing high levels of IL-6, IFN-gamma, and TNF-alpha.
   • Symptoms: High fever ($>38.0^\circ ext{C}$), hypotension, hypoxia, tachypnea, organ dysfunction.
   • Grading & Management:
     • Grade 1 (Fever only): Supportive care, antipyretics, workup for infection.
     • Grade 2 (Hypotension responsive to fluids; low-flow oxygen $\le 6 ext{L}$): Tocilizumab 8 mg/kg IV (IL-6 receptor antagonist; repeat q8h up to 4 doses total).
     • Grade 3–4 (Hypotension requiring vasopressors; high-flow oxygen/mechanical ventilation): Tocilizumab + High-dose Dexamethasone 10–20 mg IV q6h.
2. Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS):
   • Symptoms: Impaired handwriting (dysgraphia - early sensitive sign), expressive aphasia, confusion, lethargy, tremors, seizures, cerebral edema.
   • Assessment: Administer ICE (Immune Effector Cell Encephalopathy) score shiftly.
   • Management: Tocilizumab does NOT cross the blood-brain barrier and is ineffective for isolated ICANS. Treat ICANS primarily with Dexamethasone 10–20 mg IV q6h (or methylprednisolone 1,000 mg/day IV for severe cerebral edema).